Not available
Quote | Viracta Therapeutics Inc Com (NASDAQ:SNSS)
Last: | $5.32 |
---|---|
Change Percent: | 24.3% |
Open: | $4.67 |
Close: | $5.32 |
High: | $7.0864 |
Low: | $4.67 |
Volume: | 69,934,277 |
Last Trade Date Time: | 02/24/2021 04:56:00 pm |
News | Viracta Therapeutics Inc Com (NASDAQ:SNSS)
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement Shares of Viracta to commence trading on the Nasdaq Global Select Market on February 25, 2021 under ticker symbol 'VIRX' Cash and cash equivalents of over $120 million as...
Sunesis Pharmaceuticals ([[SNSS]] +32.5%) is extending yesterday’s double-digit gain after announcing the company’s financial results for the year 2020.Per the 10-K submitted today, the company’s diluted net loss per share for Q4 2020 has dropped ~68.1% YoY to $0.15&...
Message Board Posts | Viracta Therapeutics Inc Com (NASDAQ:SNSS)
Subject | By | Source | When |
---|---|---|---|
HammerTime ! | NASDAQ2020 | investorshub | 11/23/2021 2:12:58 AM |
Hammertime $SNSS | NASDAQ2020 | investorshub | 04/20/2021 7:11:14 PM |
https://www.prnewswire.com/news-releases/viracta-therapeutics-announces-closing- | Dspetry | investorshub | 02/25/2021 5:08:05 AM |
* * $SNSS Video Chart 02-24-2021 * * | ClayTrader | investorshub | 02/24/2021 9:41:58 PM |
Why would anyone sell while its going up | Jaydixson1 | investorshub | 02/24/2021 3:29:54 PM |
News, Short Squeeze, Breakout and More Instantly...
Viracta Therapeutics Inc Com Company Name:
SNSS Stock Symbol:
NASDAQ Market:
Viracta Therapeutics Inc Com Website:
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement Shares of Viracta to commence trading on the Nasdaq Global Select Market on February 25, 2021 under ticker symbol 'VIRX' Cash and cash equivalents of over $120 million as...
There’s Blood In The Streets, But Opportunity Could Be Presenting Itself With Penny Stocks What’s your strategy for finding the best penny stocks to buy ? At the top of my mind, there are a few things to look at. One of them is industry sentiment. Several industries ha...
Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma Resulting patent to extend Viracta's intellectual property protection into at least 20...